Compositions and methods for monitoring biometric indicators

A method for measuring hematocrit of a mammalian subject comprising:

• (a) providing an injectate comprising:
• (i) a first fluorescent marker having a first excitation wavelength and a first emission wavelength;
• (ii) a second fluorescent marker having a second excitation wavelength and a second emission wavelength;
• and
• (iii) an injectate carrier;
• wherein the first fluorescent marker is associated with a dynamic molecule, and the second fluorescent marker is associated with a static molecule;
• (b) calibrating the injectate to obtain a calibration identification of the injectate containing parameters of the injectate;
• (c) inputting the parameters of the calibration identification of the injectate to a fluorescent detector to calibrate the fluorescent detector;
• (d) obtaining a species specific hematocrit curve;
• (e) introducing the injectate into the vascular system of the mammalian subject;
• (f) exciting the first fluorescent marker with a first excitation wavelength and exciting the second fluorescent marker with a second excitation wavelength at an optical interface of an optical probe and the vascular system, or a sample taken from the vascular system;
• (g) measuring the first emission intensity of the first emission wavelength of the first fluorescent marker and measuring the second emission intensity of the second fluorescent marker at the optical interface of the optical probe and the vascular system, or a sample taken from the vascular system, using the calibrated fluorescent detector to obtain a spectrometric data set comprising a first emission fluorescent intensity curve from the first fluorescent marker and a second emission fluorescent intensity curve from the second fluorescent marker;
• (h) obtaining a ratio of the first fluorescent marker to the second fluorescent marker at T0 from the spectrometric data set to determine an apparent hematocrit of the subject from the species specific hematocrit curve;
• (i) obtaining a correction factor for determining the hematocrit of the mammalian subject;
• and
• (j) applying the correction factor to the apparent hematocrit to determine the hematocrit of the mammalian subject.

An injectate for measuring hematocrit of a mammalian subject comprising:

• (a) a static marker having a first fluorescent tag and a second fluorescent tag, wherein the first fluorescent tag has a first excitation wavelength and a first emission wavelength, and the second fluorescent tag has a second excitation wavelength and a second emission wavelength;
• and
• (b) an injectate carrier;
• wherein the injectate has undergone calibration to provide a calibration identification containing parameters of the injectate.

A method for measuring hematocrit of a mammalian subject comprising:

• (a) providing an injectate comprising:
• (i) a static marker having a first fluorescent tag and a second fluorescent tag, wherein the first fluorescent tag having a first excitation wavelength and a first emission wavelength and the second fluorescent tag having a second excitation wavelength and a second emission wavelength;
• and
• (ii) an injectate carrier;
• (b) calibrating the injectate to obtain a calibration identification of the injectate containing parameters of the injectate;
• (c) inputting the parameters of the calibration identification of the injectate to a fluorescent detector to calibrate the fluorescent detector;
• (d) obtaining a species specific hematocrit curve;
• (e) introducing the injectate into vascular system of the mammalian subject;
• (f) exciting the first fluorescent tag with a first excitation wavelength and exciting the second fluorescent tag with a second excitation wavelength at an optical interface of an optical probe and the vascular system, or a sample taken from the vascular system;
• (g) measuring the first emission intensity of the first emission wavelength of the first fluorescent tag and measuring the second intensity of the second emission wavelength of the second fluorescent tag at the optical interface of the optical probe and the vascular system, or at a sample taken from the vascular system, using the calibrated fluorescent detector to obtain a spectrometric data set comprising a first emission fluorescent intensity curve from the first fluorescent tag and a second emission fluorescent intensity curve from the second fluorescent tag;
• (h) obtaining a ratio of the first fluorescent tag to the second fluorescent tag at T0 from the spectrometric data set to determine an apparent hematocrit of the subject from the spectrometric data set to determine an apparent hematocrit of the subject from the species specific hematocrit curve;
• (i) obtaining a correction factor for determining the hematocrit of the mammalian subject;
• and
• (j) applying the correction factor to the apparent hematocrit to determine the hematocrit of the mammalian subject.

An oral probe for use within oral cavity of a mammalian subject for measuring fluorescent intensity of a fluorescent molecule in vascular system of the mammalian subject comprising:

• (a) a longitudinal optical conduit having a proximal end and a distal end;
• (b) an optical interface at the distal end of the optical conduit;
• and
• (c) an oral stabilizing guide to limit movement of the optical conduit within the oral cavity;
• wherein fluorescent intensity of a fluorescent molecule in the vascular system is transmitted from the vascular system to the optical conduit through the optical interface at the distal end of the optical conduit to the proximal end of the optical conduit.

A method for measuring the glomerular filtration rate (GFR) of a mammalian subject comprising:

• (a) providing an injectate comprising:
• (i) a first fluorescent marker having a first excitation wavelength and a first emission wavelength;
• (ii) a second fluorescent marker having a second excitation wavelength and a second emission wavelength;
• and
• (iii) an injectate carrier;
• wherein the first fluorescent marker is associated with a dynamic molecule, and the second fluorescent marker is associated with a static molecule;
• (b) introducing the injectate into the vascular system of the mammalian subject;
• (c) exciting the first fluorescent marker with a first excitation wavelength and exciting the second fluorescent marker with a second excitation wavelength at an optical interface of an optical probe and a sample taken from the vascular system at periodic intervals;
• (d) measuring the first emission intensity of the first emission wavelength of the first fluorescent marker and the second emission intensity of the second fluorescent marker of the sample using a fluorescent detector to obtain a spectrometric data set comprising a measured ratio of the concentration of the first fluorescent marker to the second fluorescent marker at 10 to 60 minute intervals, and a predicted concentration of the first fluorescent marker at T0, and subsequent data points taken from samples over a time period of 1 to 2 hours to determine the GFR for the mammal.